Skip to main content
SpringerLink
Log in

Ziconotide: profile report

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Lyseng-Williamson KA, Perry C. Ziconotide. CNS Drugs 2006; 20(4): 331–8

    Article  PubMed  CAS  Google Scholar 

  2. Staats P. Ziconotide: a viewpoint. CNS Drugs 2006; 20(4): 339

    Article  Google Scholar 

  3. Yaksh TL. Ziconotide: a viewpoint. CNS Drugs 2006; 20(4): 340–1

    Article  Google Scholar 

  4. Hassenbusch SJ, Garber J, Buchser E, et al. Alternative intrathecal agents for the treatment of pain. Neuromodulation 1999; 2(2): 85–91

    Article  PubMed  CAS  Google Scholar 

  5. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004 Jan 7; 291(1): 63–70

    Article  PubMed  CAS  Google Scholar 

  6. Bowersox SS, Luther R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 1998; 36(11): 1651–8

    Article  PubMed  CAS  Google Scholar 

  7. Dougherty PM, Staats PS. Intrathecal drug therapy for chronic pain: from basic science to clinical practice. Anesthesiology 1999 Dec; 91(6): 1891–918

    Article  PubMed  CAS  Google Scholar 

  8. Gaur S, Newcomb R, Rivnay B, et al. Calcium channel antagonist peptides define several components of transmitter release in the hippocampus. Neuropharmacology 1994; 33: 1211–9

    Article  PubMed  CAS  Google Scholar 

  9. Nadasdi L, Yamashiro D, Chung D, et al. Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. Biochemistry (Mosc) 1995; 34: 8076–81

    Article  CAS  Google Scholar 

  10. Wang Y-X, Bowersox SS. Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels. CNS Drug Rev 2000; 6(1): 1–20

    Article  CAS  Google Scholar 

  11. Mathur VS. Ziconotide: a new pharmacological class of drug for the management of pain. Semin Anes 2000; 19(2): 67–75

    CAS  Google Scholar 

  12. European Medicines Evaluation Agency. Ziconotide: scientific discussion [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 Jan 8]

  13. Wallace M, Ludington E, Ellis D, et al. A randomized, double-blind, placebo-controlled study of intrathecal (IT) ziconotide in adults with severe chronic pain [abstract no. 1376-P246]. 11th World Congress on Pain; 2005 Aug 21–26; Sydney

  14. Staats P, Wallace M, Presley D, et al. Long-term intrathecal ziconotide effectiveness in chronic malignant and nonmalignant pain [abstract no. 785]. J Pain 2004 Apr; 5(3 Suppl. 1): 55

    Google Scholar 

  15. Staats P, Charapata S, Royal M, et al. The safety profile of intrathecal ziconotide: a new non-opioid analgesic [abstract no. 839 plus poster]. 19th Annual Scientific Meeting of the American Pain Society; 2000 Nov 2–5; Atlanta (GA)

  16. Gee L, Marmon T, Narayana A, et al. Characterization of nervous system events in patients taking intrathecal (IT) ziconotide for severe chronic pain [abstract no. 1370-P240]. 11th World Congress on Pain; 2005 Aug 21–26; Sydney

  17. Ventafridda V, Spoldi E, Caraceni A, et al. Intraspinal morphine for cancer pain. Acta Anaesthesiol Scand Suppl 1987; 85: 47–53

    Article  PubMed  CAS  Google Scholar 

  18. Staats P. Cancer pain: beyond the ladder. J Back Musculoskeletal Rehabil 1998; 10: 69–80

    Article  Google Scholar 

  19. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy: a survey of clinical trends and decision making. J Pain Symptom Manage 2000; 20(2): S4–11

    Article  PubMed  CAS  Google Scholar 

  20. Jacox A, Carr D, Payne R. New clinical-practice guideline for the management of pain in patients with cancer. N Engl J Med 1994; 330: 651–5

    Article  PubMed  CAS  Google Scholar 

  21. Mathur VS, McGuire D, Bowersox S, et al. Neuronal N-type calcium channels: new prospect in pain therapy. Pharm News 1998; 5: 25–9

    CAS  Google Scholar 

  22. Yaksh TL. Preclinical models of nociception. In: Yaksh TL, Lynch III C, Zapol WM, et al., editors. Anesthesia: biologic foundations. Philadelphia (PA): Lippincott-Raven, 1997: 685–718

    Google Scholar 

  23. Yaksh TL, Rathbun ML, Provencher JC. Preclinical safety evaluation for spinal drugs. In: Yaksh TL, editor. Spinal drug delivery. Amsterdam: Elsevier Science, 1999: 417–37

    Google Scholar 

  24. Yaksh TL, Provencher J, de Kater AW, et al. Kinetics of ziconotide given intrathecally in dog. Toxicol Sci 1998; 48: 213

    Google Scholar 

  25. Ridgeway B, Benham CD, Gerayli A. Ziconotide for the treatment of severe spasticity after spinal cord injury. Pain 2000; 85(1–2): 287–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ziconotide: profile report. Drugs Ther. Perspect 22, 7–9 (2006). https://doi.org/10.2165/00042310-200622080-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622080-00002

Search

Navigation